[144] Adaptive Biotechnologies Corp SEC Filing
Rhea-AI Filing Summary
Adaptive Biotechnologies insider sale reported: Chad M. Robins reported multiple sales of Common Stock under Rule 144, with transactions dated between
Positive
- None.
Negative
- None.
Insights
Multiple Rule 144 sales by CEO reported across January–March 2026.
The filings list repeated dispositions of Common Stock by Chad M. Robins, showing individual trade sizes such as 41,666, 99,225, and 116,334 shares with per‑lot proceeds in USD.
These are compliance‑style disclosures under resale rules; cash‑flow recipients and broader ownership impact require referenced holdings or subsequent filings to assess materiality.